No, it's just a confused bunch of hype.
The Enterobacteraceae are a large family of bacteria that inhabit mammalian guts, and includes many common genera like Escherichia and Salmonella. There are billions of them in you right now.
Recently, a few strains have been found that are resistant to carbapenem. Bacteria often swap resistance genes around amongst themselves. So there is the potential for carbapenem-resistance to spread.
It costs them energy to do that, so these resistance genes are unlikely to be maintained unless there is an ongoing selective advantage. Such as in a patient undergoing carbapenem therapy. Sometimes genes do more than one thing, so there can be selective advantages that we don't know about.